Browse

Clinical efficacy of the gonadotropin-releasing hormone antagonist, ganirelix, in Korean women undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer with recombinant follicle-stimulating hormone

Cited 2 time in Web of Science Cited 2 time in Scopus
Authors
Moon, Shin Yong; Ku, Seung-Yup; Kim, Sun Mie; Jee, Byung Chul; Suh, Chang Suk; Choi, Young Min; Kim, Jung Gu; Kim, Seok Hyun
Issue Date
2005-05-27
Publisher
Wiley-Blackwell
Citation
J Obstet Gynaecol Res. 2005 Jun;31(3):227-35.
Keywords
Adult*Embryo TransferFemale*Fertilization in VitroFollicle Stimulating Hormone, Human/administration & dosageGonadotropin-Releasing Hormone/*administration & dosage/*analogs &derivatives/*antagonists & inhibitorsHormone Antagonists/*administration & dosageHumansInfant, NewbornMale*Ovulation InductionPregnancyPregnancy RateTreatment Outcome
Abstract
AIM: To assess the clinical efficacy and safety of the gonadotropin-releasing hormone (GnRH) antagonist, ganirelix (Orgalutran), treatment in women undergoing controlled ovarian hyperstimulation (COH) for in vitro fertilization and embryo transfer (IVF-ET) in Korean women. METHODS: This was a non-comparative, open-label, single-center trial carried out on 31 infertile Korean women. A daily dose of 0.25 mg of the GnRH antagonist, ganirelix, was given, beginning on the sixth day of recombinant follicle-stimulating hormone (FSH) treatment. If the ovarian response was low, ganirelix treatment was delayed until the leading follicle reached a mean diameter of 14 mm. The ganirelix treatment was continued until the day of human chorionic gonadotropin (hCG) injection. Descriptive statistics were recorded for all parameters. RESULTS: The median duration of ganirelix treatment was 4 days (range: 2-6 days) and the median total recombinant FSH dose was 1350 IU (900-2350 IU). During ganirelix treatment, the incidence of luteinizing hormone (LH) rises (LH = 10 IU/L) was 3.2% (one of 31 cases). On the day ovulation was triggered by hCG, the mean number of follicles >/=11 mm in diameter was 12.4 +/- 4.5, and the median of serum estradiol concentration was 4289.9 (1893.7-8268.5) pmol/L. The mean number of oocytes per retrieval was 10.9 +/- 6.1. The fertilization rate was 61.5%, and the mean number of replaced embryos was 2.8 +/- 0.6. The mean implantation rate was 10.0%, and the clinical pregnancy rate per transfer was 23.3% (seven of 30 cases) and the ongoing pregnancy rate per transfer was 20.0% (six of 30 cases). CONCLUSION: The results of the present study support ganirelix as a safe, short, convenient and effective treatment for patients undergoing COH for IVF in Korean women.
ISSN
1341-8076 (Print)
Language
English
URI
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15916659

http://hdl.handle.net/10371/15556
DOI
https://doi.org/10.1111/j.1447-0756.2005.00277.x
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Obstetrics & Gynecology (산부인과전공)Journal Papers (저널논문_산부인과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse